Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2R | P25116 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.49 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5476584 | 0.82 | TSPO (0.62) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL484344 | 0.75 | F2R (0.57) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL5148368 | 0.75 | CXCR3 (0.54) | HTTLMNAMAPT | |
| SCHEMBL17329330 | 0.73 | MMP2 (0.67) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL15360160 | 0.73 | THRB (0.58) | HTTPOLBLMNA | |
| SCHEMBL14470429 | 0.73 | F2R (0.61) | F2RCYP1A2CYP2D6HTTCXCR4 | |
| SCHEMBL20556851 | 0.72 | F2R (0.54) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL5447984 | 0.72 | POLB (0.58) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL5468418 | 0.72 | POLB (0.55) | F2RCYP1A2CYP2D6HTTPOLB | |
| SCHEMBL15357756 | 0.70 | LMNA (0.55) | POLBLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101405000-A | 2-imino-benzimidazoles | ABBOTT LAB (US) | 2009-04-08 | — | — | CN | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| US-20070232673-A1 | 2-Imino-benzimidazoles | ABBOTT LABORATORIES | 2007-10-04 | — | — | US | disclosed |
| WO-2007084728-A2 | 2-IMINO-BENZIMIDAZOLES | ABBOTT LABORATORIES (US) | 2007-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232673-A1 | 2-Imino-benzimidazoles | CYP2C19, UGT2B7, UGT2B17 | F2R 2748/4885CYP1A2 9/4885CYP2D6 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.